A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Neurocrine Biosciences
Summary
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Key Inclusion Criteria: * Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder. * Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression. * Participant must have been taking oral antidepressants for at least 8 weeks prior to screening. * Willing and able to comply with all study procedures and restrictions in the opinion of the investigator. Key Exclusion Criteria: * A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment othe…
Interventions
- DrugNBI-1065845
NBI-1065845 tablets
Locations (87)
- Neurocrine Clinical SiteHuntsville, Alabama
- Neurocrine Clinical SiteBryant, Arkansas
- Neurocrine Clinical SiteLittle Rock, Arkansas
- Neurocrine Clinical SiteGlendale, California
- Neurocrine Clinical SiteLos Angeles, California
- Neurocrine Clinical SiteOceanside, California